In the pivotal trials, adverse events were considered mild to moderate. Many adverse reactions associated with DIACOMIT can be predicted and managed, and most are consistent with class therapy.1
The most common side effects, occurring in 10% or more of patients treated with DIACOMIT and more frequently than placebo, included:1
Somnolence and decreased appetite can be managed, or even reversed, with dose adjustments to clobazam and valproate, respectively.1
Reduce clobazam by 25%
Reduce valproate by 30% per week
1. DIACOMIT® [prescribing information]. Beauvais, France: Biocodex, Inc.; July 2022. 2. DIACOMIT Periodic Benefit-Risk Evaluation Reports (PBRERs). Beauvais, France: Biocodex, Inc.; January 2022.